Does Management Matter?
This article was triggered by a beverage-induced discussion I had with Martin Eglitis at BIO-Europe earlier this month. In my licensing courses, I spend a bit of time talking about the probability…
This article was triggered by a beverage-induced discussion I had with Martin Eglitis at BIO-Europe earlier this month. In my licensing courses, I spend a bit of time talking about the probability…
Congratulations! You have successfully advanced your drug candidate to the point where it is ready for out-licensing (or so you believe, anyway). You believe that now is the time to…
The US FDA recently published an interesting discussion paper, entitled Using Artificial Intelligence & Machine Learning in the Development of Drug and Biological Products. Here is a link to the…
It seems as if nobody talks about anything except AI these days, especially in the drug discovery part of our industry. And why not? In a relatively short period of…
Biotech industry poised for boom: 2023 licensing & M&A predictions.
Why don't companies write business plans anymore? Are they useless? Is it simply faster to put together 10 slides? In this post, we discuss this interesting question.
https://youtu.be/69azx95XaGQ Here is our annual year in review, along with some predictions (which are rarely correct) for 2023.
https://youtu.be/nXkNQpLNz-M We recently completed a Scouting project on behalf of a geographically-focused company. In this video, we discuss some of the lessons learned. We also provide some suggestions for addressing…
Still working on that wave? Like many of you, I am also knee-deep in last minute preparations for BIO. For many of us, this will be the first live partnering…
Easier said than done... Consider the following scenario… You are the CEO of an emerging biotech company. You have managed to raise enough capital to advance a small molecule through…